Drugs for Early-Stage Alzheimer’s (good New York Times editorial):
“The Food and Drug Administration has proposed lowering the bar for approving drugs to treat people at the earliest stages of Alzheimer’s disease, before they have developed any serious impairment or overt dementia. The goal is commendable — to find ways to prevent or slow the progression of this terrible disease before it can rob people of their mental capacities. But the proposal raises troubling questions as to whether the agency would end up approving drugs that provide little or no clinical benefit yet Read the rest of this entry »
By: Alvaro Fernandez
Here you are several recent articles quoting SharpBrains and our new Digital Brain Health market report –which I’ll discuss today at ESCoNS2:
Just a quick note: we’ll host a webinar on January 30th to discuss key market predictions based on “The Digital Brain Health Market 2012–2020: Web-based, mobile and biometrics-based technology to assess, monitor and enhance cognition and brain functioning”, our new market report.
Here are 10 predictions, many of which will likely be realized before the end of 2013: Read the rest of this entry »
Israeli medical device offers new Alzheimer’s treatment (Reuters):
“According to Alvaro Pascual-Leone, director of the hospital’s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation — or transcranial magnetic stimulation — involves a very low current applied to a specific part of the brain and Read the rest of this entry »
We are pleased to confirm a “dream team” of 30+ Speakers and Moderators to help answer the following ten core questions on the future of brain health on June 7th and 8th. Please note that Summit registration is open now, including special Very Early Bird rates until March 31st.
By the year 2015, …
- What new tools and techniques will be available to and widely used by consumers and patients to monitor their own Brain Health?
- How will healthcare providers monitor the Brain Health of populations and individuals?
- How will companies enhance employee brain health and productivity via workplace initiatives? Read the rest of this entry »
By: Dr. Evian Gordon
(Editor’s Note: this is Part 3 of the new 3-part series written by Dr. Evian Gordon drawing from his participation at the Personalized Medicine World Congress on January, 23, 2012 at Stanford University.)
Working with Health Care Industry Stakeholders: Clinicians, Pharma/Biotech, Payers, PBMs, Lawyers, Medicare, FDA
Clinicians seek clear validated “rules of thumb” that can be easily implemented and fit into their workflow and reimbursement regime. Many are exploring “Clinical Decision Support (CDS)” tools on the web and solutions linked to “Electronic Health Records” (EHR’s). CDC and EHR’s are seeding the ground for clinicians to adopt robust Biomarkers that are shown to be unambiguously clinically relevant.
Read the rest of this entry »
By: Dr. Evian Gordon
(Editor’s Note: this is Part 1 of the new 3-part series written by Dr. Evian Gordon drawing from his participation at the Personalized Medicine World Congress on January, 23, 2012 at Stanford University.)
On average, the medications prescribed for brain-related conditions benefit approximately 50% of patients. But which 50%?
Personalized Medicine seeks to move away from the current “1 size fits all, trial and error” approach that has been necessary because of a lack of evidence. Instead, it focuses on Read the rest of this entry »